OpenURL Connection Search

Select item for more details and to access through your institution.

Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
Published in:
Nephrology Dialysis Transplantation, 2022, v. 37, n. 9, p. 1647, doi. 10.1093/ndt/gfab335
By:
- Wheeler, David C;
- Jongs, Niels;
- Stefansson, Bergur V;
- Chertow, Glenn M;
- Greene, Tom;
- Hou, Fan Fan;
- Langkilde, Anna Maria;
- McMurray, John J V;
- Rossing, Peter;
- Nowicki, Michal;
- Wittmann, István;
- Correa-Rotter, Ricardo;
- Sjöström, C David;
- Toto, Robert D;
- Heerspink, Hiddo J L;
- Investigators, DAPA-CKD Trial Committees and
Publication type:
Article
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Published in:
Nephrology Dialysis Transplantation, 2020, v. 35, n. 10, p. 1700, doi. 10.1093/ndt/gfaa234
By:
- Wheeler, David C;
- Stefansson, Bergur V;
- Batiushin, Mikhail;
- Bilchenko, Oleksandr;
- Cherney, David Z I;
- Chertow, Glenn M;
- Douthat, Walter;
- Dwyer, Jamie P;
- Escudero, Elizabeth;
- Pecoits-Filho, Roberto;
- Furuland, Hans;
- Górriz, José Luis;
- Greene, Tom;
- Haller, Hermann;
- Hou, Fan Fan;
- Kang, Shin-Wook;
- Isidto, Rey;
- Khullar, Dinesh;
- Mark, Patrick B;
- McMurray, John J V
Publication type:
Article
Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.
Published in:
Nephrology Dialysis Transplantation, 2020, v. 35, n. 9, p. 1570, doi. 10.1093/ndt/gfz064
By:
- Idzerda, Nienke M A;
- Stefansson, Bergur V;
- Pena, Michelle J;
- Sjostrom, David C;
- Wheeler, David C;
- Heerspink, Hiddo J L
Publication type:
Article
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Published in:
Nephrology Dialysis Transplantation, 2020, v. 35, n. 2, p. 274, doi. 10.1093/ndt/gfz290
By:
- Heerspink, Hiddo J L;
- Stefansson, Bergur V;
- Chertow, Glenn M;
- Correa-Rotter, Ricardo;
- Greene, Tom;
- Hou, Fan-Fan;
- Lindberg, Magnus;
- McMurray, John;
- Rossing, Peter;
- Toto, Roberto;
- Langkilde, Anna Maria;
- Wheeler, David C;
- Investigators, for the DAPA-CKD
Publication type:
Article
Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease.
Published in:
Nephrology Dialysis Transplantation, 2018, v. 33, n. 11, p. 2005, doi. 10.1093/ndt/gfx350
By:
- Dekkers, Claire C J;
- Wheeler, David C;
- Sjöström, C David;
- Stefansson, Bergur V;
- Cain, Valerie;
- Heerspink, Hiddo J L
Publication type:
Article
Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus.
Published in:
2018
By:
- Go, Alan S.;
- Yang, Jingrong;
- Tan, Thida C.;
- Cabrera, Claudia S.;
- Stefansson, Bergur V.;
- Greasley, Peter J.;
- Ordonez, Juan D.;
- for the Kaiser Permanente Northern California CKD Outcomes Study;
- Kaiser Permanente Northern California CKD Outcomes Study
Publication type:
journal article
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Published in:
Diabetologia, 2022, v. 65, n. 7, p. 1085, doi. 10.1007/s00125-022-05694-6
By:
- Waijer, Simke W.;
- Vart, Priya;
- Cherney, David Z. I.;
- Chertow, Glenn M.;
- Jongs, Niels;
- Langkilde, Anna Maria;
- Mann, Johannes F. E.;
- Mosenzon, Ofri;
- McMurray, John J. V.;
- Rossing, Peter;
- Correa-Rotter, Ricardo;
- Stefansson, Bergur V.;
- Toto, Robert D.;
- Wheeler, David C.;
- Heerspink, Hiddo J. L.
Publication type:
Article
Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease.
Published in:
Diabetes, Obesity & Metabolism, 2022, v. 24, n. 5, p. 827, doi. 10.1111/dom.14641
By:
- Chertow, Glenn M.;
- Vart, Priya;
- Jongs, Niels;
- Langkilde, Anna Maria;
- McMurray, John J. V.;
- Correa‐Rotter, Ricardo;
- Rossing, Peter;
- Sjöström, C. David;
- Stefansson, Bergur V.;
- Toto, Robert D.;
- Wheeler, David C.;
- Heerspink, Hiddo J. L.
Publication type:
Article
The effects of dapagliflozin on cardio‐renal risk factors in patients with type 2 diabetes with or without renin‐angiotensin system inhibitor treatment: a post hoc analysis.
Published in:
Diabetes, Obesity & Metabolism, 2020, v. 22, n. 4, p. 549, doi. 10.1111/dom.13923
By:
- Scholtes, Rosalie A.;
- Raalte, Daniël H.;
- Correa‐Rotter, Ricardo;
- Toto, Robert D.;
- Heerspink, Hiddo J. L.;
- Cain, Valerie;
- Sjöström, C. David;
- Sartipy, Peter;
- Stefánsson, Bergur V.
Publication type:
Article
Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.
Published in:
Diabetes, Obesity & Metabolism, 2019, v. 21, n. 3, p. 720, doi. 10.1111/dom.13579
By:
- Heerspink, Hiddo J. L.;
- Sjöström, C. David;
- Inzucchi, Silvio E.;
- Hallow, Melissa K.;
- Cain, Valerie A.;
- Rossing, Peter;
- Stefansson, Bergur V.;
- Sartipy, Peter
Publication type:
Article
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.
Published in:
European Heart Journal, 2021, v. 42, n. 13, p. 1216, doi. 10.1093/eurheartj/ehab094
By:
- Heerspink, Hiddo J L;
- Sjöström, C David;
- Jongs, Niels;
- Chertow, Glenn M;
- Kosiborod, Mikhail;
- Hou, Fan Fan;
- McMurray, John J V;
- Rossing, Peter;
- Correa-Rotter, Ricardo;
- Kurlyandskaya, Raisa;
- Stefansson, Bergur V;
- Toto, Robert D;
- Langkilde, Anna Maria;
- Wheeler, David C;
- Investigators, for the DAPA-CKD Trial Committees and
Publication type:
Article
Erratum.
Published in:
2018
By:
- Dekkers, Claire C J;
- Wheeler, David C;
- Sjöström, C David;
- Stefansson, Bergur V;
- Cain, Valerie;
- Heerspink, Hiddo J L
Publication type:
Correction Notice
Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials.
Published in:
Advances in Therapy, 2022, v. 39, n. 1, p. 193, doi. 10.1007/s12325-021-02006-z
By:
- Garcia Sanchez, Juan Jose;
- Thompson, Juliette;
- Scott, David A.;
- Evans, Rachel;
- Rao, Naveen;
- Sörstadius, Elisabeth;
- James, Glen;
- Nolan, Stephen;
- Wittbrodt, Eric T.;
- Abdul Sultan, Alyshah;
- Stefansson, Bergur V.;
- Jackson, Dan;
- Abrams, Keith R.
Publication type:
Article
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.
Published in:
2021
By:
- Persson, Frederik;
- Rossing, Peter;
- Vart, Priya;
- Chertow, Glenn M.;
- Hou, Fan Fan;
- Jongs, Niels;
- McMurray, John J.V.;
- Correa-Rotter, Ricardo;
- Bajaj, Harpreet S.;
- Stefansson, Bergur V.;
- Toto, Robert D.;
- Langkilde, Anna Maria;
- Wheeler, David C.;
- Heerspink, Hiddo J.L.;
- DAPA-CKD Trial Committees and Investigators
Publication type:
journal article
A retrospective, longitudinal study estimating the association between interdialytic weight gain and cardiovascular events and death in hemodialysis patients.
Published in:
BMC Nephrology, 2015, v. 16, n. 1, p. 1, doi. 10.1186/s12882-015-0110-9
By:
- Cabrera, Claudia;
- Brunelli, Steven M.;
- Rosenbaum, David;
- Anum, Emmanuel;
- Ramakrishnan, Karthik;
- Jensen, Donna E.;
- Stålhammar, Nils-Olov;
- Stefánsson, Bergur V.
Publication type:
Article
A retrospective, longitudinal study estimating the association between interdialytic weight gain and cardiovascular events and death in hemodialysis patients.
Published in:
BMC Nephrology, 2015, v. 16, n. 1, p. 113, doi. 10.1186/s12882-015-0110-9
By:
- Cabrera, Claudia;
- Brunelli, Steven M.;
- Rosenbaum, David;
- Anum, Emmanuel;
- Ramakrishnan, Karthik;
- Jensen, Donna E.;
- Stålhammar, Nils-Olov;
- Stefánsson, Bergur V.
Publication type:
Article

Found: 16